Brivaracetam clinical trials
Also written Briviact and UCB34714.
How each study uses brivaracetam is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the brivaracetam studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Feb 2016 · BRIVIACT · NDA 205836 (FDA, Drugs@FDA)
- European Union
- 13 Jan 2016 · Briviact (in Italy: Nubriveo) · EMEA/H/C/003898 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 4 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 42 · Other 6
UCB Pharma (16) · UCB Biopharma SRL (10) · UCB Pharma SA (7) · UCB Biopharma S.P.R.L. (3) · University of Minnesota (2) · UCB BIOSCIENCES, Inc. (2) · Jiangxi Qingfeng Pharmaceutical Co. Ltd. (1) · Muhammad Aamir Latif (1)
Often tested with
Tested in the same studies.
Levetiracetam (3) · BRV 25 (1) · BRV 50 (1)
Studies
Open first, then newest update. How each study uses brivaracetam is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 48
- A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With SeizuresRecruitingPhase 3UCB Biopharma SRLNCT04715646Written as Brivaracetam
- Epileptic Hippocampus in Alzheimer's DiseaseNot yet recruitingPhase 1/2University of California, Los AngelesNCT05899764Written as Brivaracetam
- Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal ConditionsEnrolling by invitationPhase 1Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.NCT06762743Written as Brivaracetam Oral Solution (Test Formulation)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyCompletedPhase 3UCB Biopharma SRLNCT04666610Written as Brivaracetam
- A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyActive, not recruitingPhase 3UCB Biopharma SRLNCT06315322Written as Brivaracetam Film-coated tablet
- Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse GliomasTerminatedEarly Phase 1University of RochesterNCT05029960Written as Brivaracetam
- Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal EpilepsyCompletedPhase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.NCT07563634Written as Brivaracetam
- Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialCompletedPhase 3University of MinnesotaNCT05639946Written as brivaracetam
- A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyCompletedPhase 3UCB Biopharma SRLNCT05109234Written as Brivaracetam Film-coated tablet
- Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With EpilepsyCompletedPhase 3UCB Pharma SANCT01364597Written as Brivaracetam (BRV)
- A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With EpilepsyCompletedPhase 3UCB Biopharma SRLNCT03083665Written as Brivaracetam
- Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord InjuryCompletedPhase 1/2University of MinnesotaNCT04379011Written as Brivaracetam
- Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status EpilepticusCompletedNot applicableMuhammad Aamir LatifNCT07163572Written as Intravenous brivaracetam
- Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in EpilepsyCompletedNot applicableRESnTEC, Institute of ResearchNCT07163585Written as Brivaracetam
- A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationCompletedPhase 3UCB Biopharma SRLNCT03250377Written as Brivaracetam
- A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study ParticipantsCompletedPhase 1UCB Biopharma SRLNCT06312566Written as brivaracetam (BRV) tablet
- A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic SeizuresTerminatedPhase 3UCB Biopharma SRLNCT03325439Written as Brivaracetam (BRV) intravenous (iv)
- A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study ParticipantsCompletedPhase 1UCB Biopharma SRLNCT05315947Written as brivaracetam
- Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and AdultsCompletedPhase 3UCB PharmaNCT00368251Written as BRV 2.5 mg
- A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese SubjectsCompletedPhase 1UCB Biopharma SRLNCT04882540Written as brivaracetam
See all 48 studies that test brivaracetam →
Given beside what is tested · 1 — brivaracetam is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with brivaracetam
Codes
What other systems call brivaracetam · ClinicalTrials.gg INT004618
- MeSH (NLM) C482793brivaracetamConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) U863JGG2IABRIVARACETAMConfirmed FDA, NLM, Wikidata
- RxNorm 1739745Confirmed FDA, Wikidata
- Wikidata Q408099brivaracetamConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65270BrivaracetamOne source FDA
- DrugBank DB05541One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C482793 | brivaracetam | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | U863JGG2IA | BRIVARACETAM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1739745 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408099 | brivaracetam | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65270 | Brivaracetam | One source FDA |
| DrugBank | DB05541 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.